A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

September 29, 2027

Study Completion Date

September 29, 2027

Conditions
Breast CancerBiliary Tract CarcinomaOvarian CancerEndometrial CancerSquamous Non-Small Cell Lung Cancer
Interventions
DRUG

AZD8205

AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.

DRUG

AZD8205 and AZD2936 (Rilvegostomig)

"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."

DRUG

AZD8205 and AZD5305 (saruparib)

"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."

DRUG

AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)

"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."

Trial Locations (68)

333

RECRUITING

Research Site, Taoyuan District

704

RECRUITING

Research Site, Tainan City

1062

WITHDRAWN

Research Site, Budapest

1070

RECRUITING

Research Site, Anderlecht

1082

RECRUITING

Research Site, Budapest

1122

RECRUITING

Research Site, Budapest

3000

RECRUITING

Research Site, Leuven

3168

RECRUITING

Research Site, Clayton

4101

WITHDRAWN

Research Site, South Brisbane

6009

RECRUITING

Research Site, Nedlands

8035

RECRUITING

Research Site, Barcelona

10002

RECRUITING

Research Site, Taipei

10029

WITHDRAWN

Research Site, New York

10330

RECRUITING

Research Site, Bangkok

11259

RECRUITING

Research Site, Taipei

11725

RECRUITING

Research Site, Commack

15213

RECRUITING

Research Site, Pittsburgh

20089

RECRUITING

Research Site, Rozzano

20141

RECRUITING

Research Site, Milan

21231

RECRUITING

Research Site, Baltimore

28027

RECRUITING

Research Site, Madrid

28204

RECRUITING

Research Site, Charlotte

29010

RECRUITING

Research Site, Málaga

31008

RECRUITING

Research Site, Pamplona

34232

WITHDRAWN

Research Site, Sarasota

41125

RECRUITING

Research Site, Modena

50200

RECRUITING

Research Site, Chiang Mai

63110

RECRUITING

Research Site, St Louis

71103

RECRUITING

Research Site, Shreveport

77030

RECRUITING

Research Site, Houston

87109

RECRUITING

Research Site, Albuquerque

90404

RECRUITING

Research Site, Santa Monica

91010

RECRUITING

Research Site, Duarte

92618

RECRUITING

Research Site, Irvine

95403

RECRUITING

Research Site, Santa Rosa

100142

SUSPENDED

Research Site, Beijing

RECRUITING

Research Site, Beijing

400030

RECRUITING

Research Site, Chongqing

410013

SUSPENDED

Research Site, Changsha

RECRUITING

Research Site, Changsha

510060

COMPLETED

Research Site, Guangzhou

650118

NOT_YET_RECRUITING

Research Site, Kunming

02215

RECRUITING

Research Site, Boston

VIC 3000

RECRUITING

Research Site, Melbourne

T2N 5G2

RECRUITING

Research Site, Calgary

V5Z 4E6

RECRUITING

Research Site, Vancouver

K1H 8L6

RECRUITING

Research Site, Ottawa

M5G 2M9

RECRUITING

Research Site, Toronto

H4A 3J1

RECRUITING

Research Site, Montreal

Unknown

RECRUITING

Research Site, Shandong

00168

RECRUITING

Research Site, Roma

104-0045

RECRUITING

Research Site, Chūōku

350-1298

RECRUITING

Research Site, Hidaka-shi

277-8577

RECRUITING

Research Site, Kashiwa

135-8550

RECRUITING

Research Site, Kōtoku

830-0011

RECRUITING

Research Site, Kurume-shi

411-8777

RECRUITING

Research Site, Sunto-gun

1066 CX

RECRUITING

Research Site, Amsterdam

80-214

RECRUITING

Research Site, Gdansk

02-781

RECRUITING

Research Site, Warsaw

03080

RECRUITING

Research Site, Seoul

03722

RECRUITING

Research Site, Seoul

05505

RECRUITING

Research Site, Seoul

06351

RECRUITING

Research Site, Seoul

08908

RECRUITING

Research Site, L'Hospitalet de Llobregat

CB2 0XY

RECRUITING

Research Site, Cambridge

CF14 2TL

RECRUITING

Research Site, Cardiff

EC1A 7BE

RECRUITING

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY